The Food and Drug Administration last week authorized marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood from certain living individuals as well as samples from those recently deceased who are suspected to have died from Ebola. The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test that the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease. “Today’s marketing authorization provides another important tool in the effort to fight Ebola,” said FDA Acting Commissioner Ned Sharpless, M.D. “…This marketing authorization may provide additional assurances to health care professionals seeking to use these types of rapid diagnostics. The ability to use this test to promptly make a presumptive Ebola diagnosis could help providers to more quickly isolate patients and begin treatments that can be potentially life-saving.”

Related News Articles

Headline
The Food and Drug Administration yesterday approved the first FDA-approved vaccine to prevent Ebola in adults with Zaire ebolavirus, which killed more…
Headline
A total of 2,291 patients have been hospitalized for vaping-associated lung injuries in the states, Puerto Rico and U.S. Virgin Islands, and 48 people have…
Headline
Achieving the U.S. goal of reducing new HIV infections by 90% over 10 years will require accelerated efforts to diagnose, treat and prevent HIV, according to a…
Headline
A new Centers for Disease Control and Prevention study published today in JAMA Pediatrics reveals that nearly one in five adolescents aged 12-18 years,…
Headline
The Centers for Disease Control and Prevention today released updated guidance to help health care providers diagnose and treat patients with vaping-…
Headline
The Centers for Disease Control and Prevention yesterday updated the number of people with confirmed or probable lung injuries associated with electronic…